# AbbVie financial performance and strategic transition

> Developing situation record from CLSTR: https://clstr.news/situations/abbvie-financial-performance-and-strategic-transition
> Updated: 2026-10-30T10:48:40.000Z. Sources: 8. Developments: 2.

AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion, representing an 8.6% increase from the previous year, with a net income of $4.2 billion. The company also announced a quarterly dividend of $1.73 per share.

Following strong third-quarter results in 2026, AbbVie raised its annual adjusted profit guidance to a range of $13.95 to $13.99 per share. Quarterly revenue reached $17.4 billion, a 10.3% year-over-year increase that exceeded analyst expectations. This growth was largely driven by the immunology franchise, specifically Skyrizi and Rinvoq, which helped offset declining sales of Humira due to the loss of patent exclusivity. Skyrizi generated $5.78 billion in revenue, while Rinvoq brought in $2.71 billion. 

Additionally, the neuroscience division saw a 19% revenue increase, reaching $3.39 billion, supported by Botox Therapeutic and Vraylar. To strengthen its long-term pipeline, the company is utilizing acquisitions, including the $10.9 billion purchase of Apogee Therapeutics. The company also announced a 5.2% increase in its quarterly dividend, with higher payments scheduled to begin in February 2027.

## Claims

- AbbVie reported third-quarter revenue of $17.4 billion. (reported by 3 sources)
- The company raised its annual adjusted profit forecast to a range of $13.95 to $13.99 per share. (reported by 3 sources)
- AbbVie's adjusted profit per share for the quarter was $3.82. (reported by 3 sources)
- Skyrizi recorded quarterly sales of $5.78 billion. (reported by 2 sources)
- Rinvoq generated $2.71 billion in revenue during the quarter. (reported by 2 sources)
- AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics in June. (reported by 2 sources)
- The neuroscience division revenue increased by 19%. (reported by 1 source)
- Humira sales were $683 million for the quarter. (reported by 1 source)

## Timeline

### 2026-10-30: AbbVie raises profit guidance following strong Q3 results

AbbVie raised its 2026 profit guidance after Q3 revenue hit $17.4 billion, driven by strong sales of Skyrizi and Rinvoq.

8 sources. https://clstr.news/cluster/abbvie-raises-annual-profit-forecast-following-strong-q3-results

### 2026-10-12: AbbVie reports $61.2 billion revenue and announces quarterly dividend

AbbVie Inc. reports $61.2 billion in FY2025 revenue amid a transition to new immunology treatments and has announced a quarterly dividend of $1.73 per share.

4 sources. https://clstr.news/cluster/abbvie-reports-612-billion-revenue-and-announces-quarterly-dividend

---
Cite as: AbbVie financial performance and strategic transition. CLSTR, https://clstr.news/situations/abbvie-financial-performance-and-strategic-transition